A Phase 3 interventional study of Nivolumab in Lung Cancer and Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-18.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 24 that started in 2017, is one of 24 in phase 3, and was the 48th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 78 · Phase 3 24 · Phase 4 2
First in 2006; this study’s year is marked. 24 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 400 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 120 interventional studies. Of the 62 that completed or were terminated, 44 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 120 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb: 21 open now, 35 under way, 10 of them phase 3. Of 91 finished, 47 (52%) have results posted.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 30th largest by enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2017, is one of 27 in phase 3, and was the 63rd registered.
Bristol-Myers Squibb’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
13 of the studies testing nivolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02595944Phase 3National Cancer Institute (NCI)Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | 2027-05-31 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT06275360VA Office of Research and DevelopmentRepositioning Immunotherapy in VetArans With Lung Cancer | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Bristol-Myers Squibb’s 131 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
This study's enrollment of 400 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab administered every two weeks
Biological: Nivolumab
Intravenous infusion administered over 30 minutes at 240 mg
Also known as: Opdivo, BMS-936558
Number of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events
Number of non-HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in non-HBV infected participants. To evaluate safety and tolerability in non-HBV infected participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed during or after one prior systemic therapy and are treated with nivolumab monotherapy with an infusion duration of 30 minutes. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose up to 100 days post dose, up to approximately 36 months
Number of HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events
Number of HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in HBV participants. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose up to 100 days post dose, up to approximately 36 months
Number of Participants Experiencing Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose up to 100 days post dose, up to approximately 36 months
Overall Survival (OS)
Overall survival (OS) is defined as the time from the first dosing date to the date of death. Participants without documentation of death will be recorded on the last date the participant was known to be alive. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).
Time frame: From the first dose up to the date of death. Participants without documentation of death will be censored on the late date known to be alive, up to approximately 32 months
Progression-Free Survival (PFS)
PFS is the time from first dose to the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who die without a reported prior progression are considered to have progressed on their death date. Participants who did not progress or die will be documented on the date of their last evaluable tumor assessment. Participants who did not have any on study tumor assessments and did not die will be documented on their first dose date. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be documented at the last evaluable tumor assessment prior to initiation of the subsequent anti-cancer therapy. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC). Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: From the first dose up to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause, up to approximately 30 months
Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests
Number of Participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria
Time frame: From first dose up to 100 days post last dose, up to approximately 36 months
Number of Participants Experiencing Serious Adverse Events (SAEs)
Number of Participants experiencing SAEs are tabulated using worst grade per NCI CTCAE v.4 criteria by system organ class and MedDRA preferred term.
Time frame: From first dose to 100 days post last dose, up to 36 months
Objective Response Rate
Objective Response Rate (ORR) is defined as the percentage of all treated subjects whose best overall response (BOR) from baseline is either a CR or PR per RECIST 1.1 criteria. BOR is determined by the best response designation recorded between the first dose date and the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. For subjects without documented progression or subsequent anticancer therapy, all available response designations will contribute to the BOR determination. For subjects who continue nivolumab beyond progression, the BOR should be determined based on response designations recorded at the time of the initial RECIST 1.1 defined progression.
Time frame: From the first dose date up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. Up to approximately 36 months
Duration of Tumor Response
Duration of Response (DOR) is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who neither progress nor die will be documented on the date of their last assessment. The censoring algorithm for DOR will be the same as used for PFS definition. This endpoint will only be evaluated for participants with the best overall response of complete response or partial response.
Time frame: From the date of first confirmed response to the date of the first documented tumor progression, up to approximately 30 months
Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests
Number of participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria
Time frame: From randomization to 100 days post last dose, up to 36 months
Time to Treatment Failure (TTF)
Time to Treatment Failure is defined as the minimum of the time from treatment assignment to disease progression (determined by investigator assessments using RECIST 1.1), death or last dose date if a participant progressed, died or discontinued from treatment for any reasons other than "maximum clinical benefit" and "administrative reasons by sponsor". TTF is censored at the last dose date for participants who continued on treatment without progression (per RECIST 1.1) or death at the time of the database lock. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).
Time frame: From treatment assignment to disease progression, death or last dose date, up to approximately 16 months
| Milestone | Non-HBV Participants | HBV Participants |
|---|---|---|
| Started | 383 | 17 |
| Completed | 36 | 2 |
| Not completed | 347 | 15 |
| Withdrew: Study drug toxicity | 25 | 3 |
| Withdrew: Maximum clinical benefit | 5 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Adverse event unrelated to study drug | 19 | 2 |
| Withdrew: Disease progression | 266 | 8 |
| Withdrew: Other reasons | 10 | 0 |
| Withdrew: Participant withdrew consent | 8 | 1 |
| Withdrew: Participant no longer meets study criteria | 0 | 1 |
| Withdrew: Participant request to discontinue study treatment | 10 | 0 |
Number of non-HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in non-HBV infected participants. To evaluate safety and tolerability in non-HBV infected participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed during or after one prior systemic therapy and are treated with nivolumab monotherapy with an infusion duration of 30 minutes. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | Non-HBV Participants |
|---|---|
| Gastrointestinal Adverse | 2 |
| Hepatic Adverse Event | 8 |
| Pulmonary Adverse Event | 5 |
| Renal Adverse Event | 2 |
| Skin Adverse Event | 7 |
Number of HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in HBV participants. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | HBV Participants |
|---|---|
| Gastrointestinal Adverse Event | 0 |
| Hepatic Adverse Event | 0 |
| Pulmonary Adverse Event | 0 |
| Renal Adverse Event | 0 |
| Skin Adverse Reaction | 1 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | Non-HBV Participants | HBV Participants |
|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | 375 | 17 |
Overall survival (OS) is defined as the time from the first dosing date to the date of death. Participants without documentation of death will be recorded on the last date the participant was known to be alive. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).
| Months | Non-HBV Participants | HBV Participants | All Treated Participants |
|---|---|---|---|
| All treated participants | 14.16 (12.25 to 18.07) | 22.31 (10.02 to NA) | 14.65 (12.32 to 18.10) |
| PD-L1 < 1% | — | — | 13.31 (10.87 to 17.71) |
| PD-L1 ≥ 1% | — | — | 19.25 (12.94 to 23.46) |
| PD-L1 < 5% | — | — | 14.65 (11.63 to 18.10) |
| PD-L1 ≥ 5% | — | — | 18.37 (11.70 to 22.77) |
| PD-L1 < 10% | — | — | 14.72 (12.35 to 18.76) |
| PD-L1 ≥ 10% | — | — | 17.68 (10.78 to 21.03) |
| PD-L1 < 50% | — | — | 16.23 (12.52 to 18.86) |
| PD-L1 ≥ 50% | — | — | 14.75 (10.68 to 29.04) |
| PD-L1 Not Reportable | — | — | 11.99 (9.17 to 19.19) |
| Squamous Tumor Histology | — | — | 13.80 (10.78 to 18.37) |
| Non-squamous Tumor Histology | — | — | 14.75 (11.70 to 19.32) |
| EGFR Mutation Positive | — | — | 19.32 (11.24 to 31.74) |
| ALK translocation positive | — | — | 16.48 (1.28 to NA) |
PFS is the time from first dose to the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who die without a reported prior progression are considered to have progressed on their death date. Participants who did not progress or die will be documented on the date of their last evaluable tumor assessment. Participants who did not have any on study tumor assessments and did not die will be documented on their first dose date. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be documented at the last evaluable tumor assessment prior to initiation of the subsequent anti-cancer therapy. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC). Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Months | Non-HBV Participants | HBV Participants | All Treated Participants |
|---|---|---|---|
| All treated participants | 3.61 (2.33 to 3.75) | 2.04 (1.64 to 10.22) | 3.61 (2.33 to 3.75) |
| PD-L1 < 1% | — | — | 2.33 (1.94 to 3.68) |
| PD-L1 ≥ 1% | — | — | 4.73 (3.68 to 5.65) |
| PD-L1 < 5 | — | — | 2.37 (1.94 to 3.68) |
| PD-L1 ≥ 5 | — | — | 5.42 (3.68 to 5.65) |
| PD-L1 < 10 | — | — | 2.50 (1.94 to 3.68) |
| PD-L1 ≥ 10 | — | — | 5.45 (3.68 to 5.65) |
| PD-L1 < 50 | — | — | 3.58 (2.07 to 3.75) |
| PD-L1 ≥ 50 | — | — | 5.55 (2.23 to 7.33) |
| EGFR mutation positive | — | — | 1.87 (1.71 to 4.73) |
| ALK translocation positive | — | — | 1.91 (1.28 to 16.36) |
| Squamous subgroup | — | — | 3.75 (3.06 to 5.55) |
| Non-squamous subgroup | — | — | 2.79 (1.94 to 3.68) |
Number of Participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria
| Participants | Non-HBV Participants | HBV Participants |
|---|---|---|
| ALT OR AST > 3XULN | 16 | 1 |
| ALT OR AST > 5XULN | 5 | 0 |
| ALT OR AST > 10XULN | 4 | 0 |
| ALT OR AST > 20XULN | 2 | 0 |
| TOTAL BILIRUBIN > 2XULN | 4 | 0 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAY | 0 | 0 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN 30 DAY | 0 | 0 |
Number of Participants experiencing SAEs are tabulated using worst grade per NCI CTCAE v.4 criteria by system organ class and MedDRA preferred term.
| Participants | Non-HBV Participants | HBV Participants |
|---|---|---|
| Number of Participants Experiencing Serious Adverse Events (SAEs) | 157 | 12 |
Objective Response Rate (ORR) is defined as the percentage of all treated subjects whose best overall response (BOR) from baseline is either a CR or PR per RECIST 1.1 criteria. BOR is determined by the best response designation recorded between the first dose date and the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. For subjects without documented progression or subsequent anticancer therapy, all available response designations will contribute to the BOR determination. For subjects who continue nivolumab beyond progression, the BOR should be determined based on response designations recorded at the time of the initial RECIST 1.1 defined progression.
| Percentage of participants | Non-HBV Participants | HBV Participants | All Treated Participants |
|---|---|---|---|
| All treated participants | 14.88 (11.47 to 18.85) | 17.65 (3.80 to 43.43) | 15.00 (11.65 to 18.88) |
| Squamous tumor histology | — | — | 18.38 (12.26 to 25.93) |
| Non-squamous tumor histology | — | — | 13.26 (9.41 to 17.95) |
| PD-L1 < 1% | — | — | 6.32 (3.20 to 11.03) |
| PD-L1 ≥ 1% | — | — | 25.60 (19.18 to 32.89) |
| PD-L1 < 5% | — | — | 8.78 (5.29 to 13.52) |
| PD-L1 ≥ 5% | — | — | 26.28 (19.13 to 34.48) |
| PD-L1 < 10% | — | — | 10.81 (7.05 to 15.66) |
| PD-L1 ≥ 10% | — | — | 25.00 (17.55 to 33.73) |
| PD-L1 < 50% | — | — | 11.76 (8.19 to 16.20) |
| PD-L1 ≥ 50% | — | — | 31.43 (20.85 to 43.63) |
| EGFR mutation positive | — | — | 17.65 (6.76 to 34.53) |
| ALK translocation positive | — | — | 10.00 (0.25 to 44.50) |
Duration of Response (DOR) is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who neither progress nor die will be documented on the date of their last assessment. The censoring algorithm for DOR will be the same as used for PFS definition. This endpoint will only be evaluated for participants with the best overall response of complete response or partial response.
| Months | HBV Participants | Non-HBV Participants | All Treated Participants |
|---|---|---|---|
| All treated participants | NA (8.15 to NA) | 19.38 (11.04 to 24.97) | 19.38 (11.04 to 24.97) |
| Squamous tumor histology | — | — | 12.62 (8.11 to 25.33) |
| Non-squamous tumor histology | — | — | 19.61 (9.49 to 27.60) |
| PD-L1 < 1% | — | — | 19.38 (8.11 to 24.97) |
| PD-L1 ≥ 1% | — | — | 16.11 (9.43 to 27.60) |
| PD-L1 < 5% | — | — | 19.38 (8.11 to 24.97) |
| PD-L1 ≥ 5% | — | — | 19.61 (9.33 to 29.70) |
| PD-L1 < 10% | — | — | 12.06 (8.11 to 24.97) |
| PD-L1 ≥ 10% | — | — | 21.13 (9.43 to NA) |
| PD-L1 < 50% | — | — | 12.06 (8.15 to 24.97) |
| PD-L1 ≥ 50% | — | — | 21.49 (9.30 to NA) |
| EGFR mutation positive | — | — | 12.57 (5.59 to NA) |
| ALK translocation positive | — | — | 19.42 (NA to NA) |
Number of participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria
| Participants | Non-HBV Participants | HBV Participants |
|---|---|---|
| TSH > ULN | 87 | 1 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 63 | 0 |
| TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN | 36 | 1 |
| TSH > ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN | 52 | 0 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 74 | 1 |
| TSH < LLN | 66 | 3 |
| TSH < LLN WITH TSH >= LLN AT BASELINE | 56 | 3 |
| TSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN | 34 | 1 |
| TSH < LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN | 32 | 2 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 43 | 2 |
Time to Treatment Failure is defined as the minimum of the time from treatment assignment to disease progression (determined by investigator assessments using RECIST 1.1), death or last dose date if a participant progressed, died or discontinued from treatment for any reasons other than "maximum clinical benefit" and "administrative reasons by sponsor". TTF is censored at the last dose date for participants who continued on treatment without progression (per RECIST 1.1) or death at the time of the database lock. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).
| Months | Non-HBV Participants | HBV Participants | All Treated Participants |
|---|---|---|---|
| All treated participants | 2.23 (1.94 to 3.52) | 1.97 (1.41 to 10.22) | 2.10 (1.94 to 3.52) |
| Squamous Tumor Histology | — | — | 3.68 (2.10 to 5.45) |
| Non-Squamous Tumor Histology | — | — | 1.94 (1.87 to 2.50) |
| EGFR Mutation Positive | — | — | 1.86 (1.68 to 3.65) |
| ALK Translocation Positive | — | — | 1.91 (1.28 to 16.36) |
| PD-L1 < 1% | — | — | 1.97 (1.87 to 2.92) |
| PD-L1 ≥ 1% | — | — | 3.68 (2.17 to 5.55) |
| PD-L1 < 5% | — | — | 1.97 (1.87 to 3.06) |
| PD-L1 ≥ 5% | — | — | 3.68 (2.23 to 5.55) |
| PD-L1 < 10% | — | — | 1.97 (1.87 to 3.09) |
| PD-L1 ≥ 10% | — | — | 3.75 (2.23 to 5.55) |
| PD-L1 < 50% | — | — | 2.14 (1.91 to 3.58) |
| PD-L1 ≥ 50% | — | — | 4.11 (2.00 to 6.01) |
Collected over All-cause mortality was assessed from date of first dose to study completion (up to approximately 41 months). Serious Adverse events and other adverse events were assessed from date of first dose to 100 days following date of last dose (up to approximately 36 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Non-HBV Participants | 270/383 (70.5%) | 157/383 (41%) | 359/383 (93.7%) |
| HBV Participants | 9/17 (52.9%) | 12/17 (70.6%) | 17/17 (100%) |
| TOTAL | 279/400 (69.8%) | 169/400 (42.3%) | 376/400 (94%) |
| Event | Non-HBV Participants | HBV Participants | TOTAL |
|---|---|---|---|
| PneumoniaInfections and infestations | 29/383 | 4/17 | 33/400 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/383 | 2/17 | 8/400 |
| DeathGeneral disorders | 2/383 | 1/17 | 3/400 |
| PyrexiaGeneral disorders | 2/383 | 1/17 | 3/400 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/383 | 1/17 | 2/400 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/383 | 1/17 | 1/400 |
| HypokalaemiaMetabolism and nutrition disorders | 1/383 | 1/17 | 2/400 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/383 | 1/17 | 4/400 |
| Tumour associated feverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/383 | 1/17 | 1/400 |
| Spinal cord compressionNervous system disorders | 0/383 | 1/17 | 1/400 |
| Event | Non-HBV Participants | HBV Participants | TOTAL |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 155/383 | 7/17 | 162/400 |
| CoughRespiratory, thoracic and mediastinal disorders | 85/383 | 7/17 | 92/400 |
| PyrexiaGeneral disorders | 72/383 | 6/17 | 78/400 |
| HyponatraemiaMetabolism and nutrition disorders | 52/383 | 6/17 | 58/400 |
| Aspartate aminotransferase increasedInvestigations | 59/383 | 5/17 | 64/400 |
| Decreased appetiteMetabolism and nutrition disorders | 94/383 | 2/17 | 96/400 |
| LeukocytosisBlood and lymphatic system disorders | 21/383 | 4/17 | 25/400 |
| Alanine aminotransferase increasedInvestigations | 62/383 | 4/17 | 66/400 |
| Neutrophil count increasedInvestigations | 15/383 | 4/17 | 19/400 |
| ConstipationGastrointestinal disorders | 39/383 | 3/17 | 42/400 |
All treated participants
| Age, Continuous(Years) | Non-HBV Participants | HBV Participants | Total |
|---|---|---|---|
| Mean | 60.6 ± 8.72 | 59.1 ± 7.86 | 60.5 ± 8.68 |
| Sex: Female, Male(Participants) | Non-HBV Participants | HBV Participants | Total |
|---|---|---|---|
| Female | 82 | 4 | 86 |
| Male | 301 | 13 | 314 |
| Race/Ethnicity, Customized(Participants) | Non-HBV Participants | HBV Participants | Total |
|---|---|---|---|
| Chinese | 377 | 17 | 394 |
| Asian Other | 6 | 0 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in Jun 2021, 41 months.
Results were first posted in Jul 2024, 3 years 1 month after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 41 months is close to that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Carcinoma, Non-Small-Cell Lung →